| home | |
| CDDW 2002 | |
| Search CDDW Abstracts |
CAG CLINICAL POSTER SESSION - TUESDAY
ESOPHAGEAL, GASTRIC & DUODENAL DISORDERS
[133]
A NEW MEASURE OF QUALITY OF LIFE FOR PATIENTS WITH ACHALASIA: THE WESTERN ACHALASIA
QUESTIONNAIRE
NV
Khanna, F Rehman, HG Preiksaitis, R Reynolds, JC Gregor
Division of Gastroenterology,
University of Western Ontario, London, Ontario
[134]
DO GASTROESOPHAGEAL REFLUX DISEASE PATIENTS WITH H. PYLORI INFECTION HAVE LESS
SEVERE DISEASE THAN NON-INFECTED PATIENTS? - AN INTERIM ANALYSIS
CA
Fallone, S Mayrand, G Wakil, AN Barkun
Division of Gastroenterology,
McGill University Health Centre, Montreal, Quebec
[135]
COMPARABLE HIGHER EFFICACY OF PANTOPRAZOLE 40 MG VS. OMEPRAZOLE MUPS 40 MGIN
HIGHLY COMPLIANT IN PATIENTS WITH GERD II/III
T Körner1,
K Schütze2, RJM van Leendert3, I Fumagalli4,
B Costa Neves5; G Gatz6, M Bohuschke6
1Suhl, Germany; 2Wien,
Austria; 3Zwijndrecht, Netherlands; 4Locarno, Czech Republic;
5Portugal; 6Konstanz, Germany
[136]
SYSTEMATIC REVIEW OF UPPER GASTROINTESTINAL TOXICITY OF COX-2 INHIBITORS
E Jolicoeur,
A Rostom
Department of Gastroenterology,
University of Ottawa, Ottawa, Ontario
[137]
EQUIVALENT EFFICACY OF PANTOPRAZOLE 40 MG AND ESOMEPRAZOLE 40 MG IN PATIENTS
WITH GERD
R Eissele1, G
Gatz2, U Hole2
1Fürstenfeldbruck,
Germany; 2 Byk Gulden, Konstanz, Germany
[138]
SIMILAR REDUCTION OF SYMPTOM LOAD WITHIN 4 WEEKS OF TREATMENT WITH PANTOPRAZOLE
40 MG OR ESOMEPRAZOLE 40 MG IN PATIENTS WITH MODERATE TO SEVERE GERD
T Scholten1, U Hole2, G Gatz2
1Hagen, Germany; 2Konstanz, Germany
[139]
EOSINOPHILIC ESOPHAGITIS: REVIEW OF LOCAL EXPERIENCE AT SAINTE-JUSTINE’S HOSPITAL
AMGA Sant’Anna1,
S Rolland, JC Fournet, S Yazbeck, E Drouin
Pediatric Department, Gastroenterology Division, Pathology Department and
Surgery Department; Sainte-Justine’s Hospital. University of Montreal, Montreal,
Quebec; 1Assistant Professor, UERJ, Brazil
[140]
KNOWLEDGE, QUALITY OF LIFE AND SYMPTOM SEVERITY IN A DYSPEPSIA AND GERD PATIENT
POPULATION
R Cawdron, D Armstrong
Division of Gastroenterology,
McMaster University, Hamilton, Ontario
[141]
VALIDATING A DYSPEPSIA AND GERD KNOWLEDGE QUESTIONNAIRE (DGKQ)
R Cawdron, D Armstrong
Division of Gastroenterology, McMaster University, Hamilton, Ontario
[142]
PATIENT EDUCATIONAL RESOURCE UTILIZATION IN A DYSPEPSIA AND GERD PATIENT POPULATION
R Cawdron, D Armstrong
Division of Gastroenterology,
McMaster University, Hamilton Ontario
[143]
INITIAL PPI THERAPY IS MOST EFFECTIVE IN THE MANAGEMENT OF HEARTBURN-DOMINANT
UNINVESTIGATED DYSPEPSIA (UD) IN PRIMARY CARE PRACTICE (PCP) – THE CADET-HR
STUDY
D Armstrong1,
AN Barkun2, N Chiba1, S Veldhuyzen van Zanten3, ABR Thomson4,
S Smyth5, B Chakraborty5, P Sinclair6 and CADET-HR
Investigators
1McMaster University, Hamilton, Ontario; 2McGill University,
Montreal, Quebec; 3Dalhousie University, Halifax, Nova Scotia; 4University
of Alberta, Edmonton, Alberta; 5AstraZeneca Canada, Mississauga,
Ontario; 6INSINConsulting, Ontario
[144]
‘START HIGH’ – A BETTER ACID SUPPRESSION STRATEGY FOR HEARTBURN-DOMINANT UNINVESTIGATED
DYSPEPSIA (UD) IN PRIMARY CARE PRACTICE – THE CADET-HR STUDY
D Armstrong1,
AN Barkun2, N Chiba1, S Veldhuyzen van Zanten3, ABR Thomson4,
S Smyth5, B Chakraborty5, P Sinclair6 and CADET-HR
Investigators
1McMaster University, Hamilton, Ontario; 2McGill University,
Montreal, Quebec; 3Dalhousie University, Halifax, Nova Scotia; 4University
of Alberta, Edmonton, Alberta; 5AstraZeneca Canada, Mississauga,
Ontario; 6INSINConsulting, Ontario
[145]
SYMPTOM RELAPSE AFTER ACUTE THERAPY FOR HEARTBURN-DOMINANT UNINVESTIGATED DYSPEPSIA
(UD) IN PRIMARY CARE PRACTICE (PCP) – THE CADET-HR STUDY
D Armstrong1,
AN Barkun2, N Chiba1, S Veldhuyzen van Zanten3,
ABR Thomson4, S Smyth5, B Chakraborty5, P Sinclair6
and CADET-HR Investigators
1McMaster University, Hamilton, Ontario; 2McGill University,
Montreal, Quebec; 3Dalhousie University, Halifax, Nova Scotia; 4University
of Alberta, Edmonton, Alberta; 5AstraZeneca Canada, Mississauga,
Ontario; 6INSINConsulting, Ontario
[146]
HELICOBACTER PYLORI INFECTION IN ALBERTAN HUTTERITE CHILDREN
JL
Barkey, RB Scott, H Machida
Division of Pediatric
Gastroenterology and Nutrition, Department of Pediatrics, University of Calgary,
Calgary, Alberta
[147]
DOES ASA/NSAID USE PREDICT CLINICALLY SIGNIFICANT FINDINGS (CSFs) AT ENDOSCOPY
IN PATIENTS WITH UNINVESTIGATED DYSPEPSIA (UD)? THE CADET-PE STUDY
ABR Thomson1,
D Armstrong2, AN Barkun3, N Chiba2, S Veldhuyzen
van Zanten4, RJ White5, S Escobedo5, P Sinclair6,
and the CADET-PE Study Group7
1University of Alberta, Edmonton, Alberta; 2McMaster
University, Hamilton, Ontario; 3McGill University, Montreal, Quebec;
4Dalhousie University, Halifax, Nova Scotia; 5AstraZeneca
Canada Inc, Mississauga, Ontario; 6INSINConsulting, Ontario; 7Canada
[148]
DOES HELICOBACTER PYLORI (HP) INFECTION PREDICT CLINICALLY SIGNIFICANT
FINDS (CSFs) AT ENDOSCOPY (EGD) IN PATIENTS WITH UNINVESTIGATED DYSPEPSIA (UD)?
THE CADET-PE STUDY
ABR
Thomson1, D Armstrong2, AN Barkun3,
N Chiba2, S Veldhuyzen van Zanten4, RJ White5,
S Escobedo5, P Sinclair6, and the CADET-PE Study Group7
1University
of Alberta, Edmonton, Alberta; 2McMaster University, Hamilton, Ontario;
3McGill University, Montreal, Quebec; 4Dalhousie University,
Halifax, Nova Scotia; 5AstraZeneca Canada Inc, Mississauga, Ontario;
6INSINConsulting, Ontario; 7Canada
[149]
THE HIGH PREVALENCE OF CLINICALLY SIGNIFICANTFINDINGS (CSFs) AT ENDOSCOPY (EGD)
IN PATIENTS WITH UNINVESTIGATED DYSPEPSIA (UD) IS NOT PREDICTED BY PATIENTS’
DYSPEPSIA SYMPTOMS (CADET-PE STUDY)
ABR Thomson1,
D Armstrong2, AN Barkun3, N Chiba2, S Veldhuyzen
van Zanten4, RJ White5, S Escobedo5, P Sinclair6,
and the CADET-PE Study Group7
1University of Alberta, Edmonton, Alberta; 2McMaster
University, Hamilton, Ontario; 3McGill University, Montreal, Quebec;
4Dalhousie University, Halifax, Nova Scotia; 5AstraZeneca
Canada Inc, Mississauga, Ontario; 6INSINConsulting, Ontario; 7Canada
[150]
REFLUX SYMPTOMS SHOULD NOT BE EXCLUDED FROM THE DEFINITION OF UNINVESTIGATED
DYSPEPSIA (UD): RESULTS FROM THE CADET-Hp STUDY
N Chiba1,
SJO Veldhuyzen van Zanten2, ABR Thomson3, AN Barkun4,
D Armstrong1, P Sinclair5, S Escobedo6, and the CADET-Hp
Study Group7
1McMaster
University, Hamilton, Ontario; 2Dalhousie University, Halifax, Nova
Scotia; 3University of Alberta, Edmonton, Alberta; 4McGill
University, Montreal, Quebec; 5INSINConsulting, Ontario; 6AstraZeneca
Canada Inc, Mississauga, Ontario; 7Canada
[151]
APPROPRIATENESS OF DISCONTINUATION OF INTRAVENOUS PROTON PUMP INHIBITOR (IVPPI)
IN BLEEDING PEPTIC ULCER PATIENTS WITHOUT HIGH RISK ULCER STIGMATA AT ENDOSCOPY:
PRELIMINARY RESULTS
CN Andrews,
I Zadieh, RA Enns
Departments of Medicine/GI, St Paul’s Hospital, University of British Columbia,
Vancouver, British Columbia
[152]
COST IMPLICATIONS OF ADMINISTERING INTRAVENOUS PROTON PUMP INHIBITORS TO ALL
PATIENTS PRESENTING WITH UPPER GASTROINTESTINAL BLEEDING
Y Gagnon1 MSc, R Enns2, MA Eloubeidi3,
MR Arguedas3, K Rioux2 , A Levy1,4 PhD and
RUGBE investigators5
1OCCAM Research & Consulting
Inc,2Division of Gastroenterology, St Paul’s Hospital, University
of British Columbia, 3Division of Gastroenterology, University of
Alabama Hospital, Birmingham, Alabama; 4Department of Health Care
and Epidemiology, University of British Columbia, Vancouver, British Columbia;
5Registry of UGI Bleeding and Endoscopy
[153]
PRESCRIBING PRACTICES AND INDICATIONS FOR THE USE OF INTRAVENOUS PROTON PUMP
INHIBITORS (IV PPI) IN AN URBAN TERTIARY CARE CENTRE
I Zadieh1, C Andrews1, M Brodie1,
M Fishman2, M Hahn3, K Atkinson4, J Grey5,
R Enns1
1St Paul’s Hospital, University of British Columbia, Vancouver;
2Richmond General Hospital, Richmond; 3Lion’s Gate Hospital,
Vancouver; 4Royal Columbian Hospital, New Westminster; and 5Vancouver
General Hospital, University of British Columbia, Vancouver, British Columbia